Chemomab Therapeutics Ltd. (NASDAQ: CMMB)
$1.11
+0.0300 ( +2.78% ) 59.5K
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.
Market Data
Open
$1.11
Previous close
$1.08
Volume
59.5K
Market cap
$15.93M
Day range
$1.07 - $1.16
52 week range
$0.42 - $1.46
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
6-k | Quarterly Reports | 1 | Jun 12, 2024 |
6-k | Quarterly Reports | 3 | May 09, 2024 |
6-k | Quarterly Reports | 3 | May 08, 2024 |
6-k | Quarterly Reports | 5 | May 03, 2024 |
20-f | Annual reports | 97 | Mar 28, 2024 |
6-k | Quarterly Reports | 3 | Mar 07, 2024 |
6-k | Quarterly Reports | 3 | Jan 03, 2024 |
6-k | Quarterly Reports | 4 | Nov 09, 2023 |
6-k | Quarterly Reports | 28 | Aug 14, 2023 |
6-k | Quarterly Reports | 1 | Aug 08, 2023 |